BIO report makes case for 14 years of biosimilar exclusivity
This article was originally published in Scrip
US biosimilars legislation with less than 14 years of innovator data exclusivity would give the federal government little additional cost savings, but would spur a drop in biotechnology R&D by at least $41 billion, a new report commissioned by the trade group BIOsays.
You may also be interested in...
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.